Press release
GeneNova Press-release
Swedish academia and industry join forces to develop new platform for gene therapy. Download pressrelease here
Genenova
innovation milieu
for a safer, more efficiacious and accessible AAV gene therapy
making gene therapy accessible
While being probably the most transformative change of therapy in centuries, allowing a genetic cure to disease and not just relieve of symptom, AAV based gene therapy is still only accessible for a fraction of the patients in need.
We want to change this and allow for addressing of previously
un-targeted indications and making it accesible to more patients.
Our vision is to innovate AAV bioproduction and provide a platform aimed at order of magnitudes improvement compared to state-of-art today.
We do this by combining expertise from experts of different areas aligning world-leading Swedish faculty within cellbiology,
pharmacology, systems biology, neurology, drug discovery, industrial biotechnology, and
mathematics with Swedish global commercial technology, service providers and
biopharmaceutical companies to one goal – to enable the sustainable access to curative treatment by AAV for the patient. GeneNova is funded by partner companies and VINNOVA Sweden's innovation agency 2021-2026
Director Prof. Johan Rockberg KTH - contact us for more info
Genenova updates
News
Cell Reports paper published
Highly secreted proteins need more ATP, avoid stress and have particular ribosomes arrangement
Check out our recently published paper in Cell reports
Metabolic engineering paper published
Lessons of proteins' way out of our cells guide improved cell lines
Some proteins produce better in HEK293 than CHO. We tried to learn from this to improve secretion of proteins in CHO. Check out our recently published paper in Metabolic engineering
